Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Renuris is a specialized nutritional supplement developed by Steadfast Medishield for the management of malnutrition in patients with end-stage renal disease (ESRD) who are undergoing maintenance dialysis, including both hemodialysis and peritoneal dialysis. Formulated as a sugar-free, orange-flavored powder, it contains high concentrations of whey protein as its primary active ingredient. The product is enriched with essential amino acids, including branched-chain amino acids (BCAAs) which constitute 25% of the protein content, as well as vitamins (A, E, B2, folic acid, and biotin), antioxidants, L-carnitine, and taurine. Renuris is specifically designed to provide high biological value protein while remaining low in electrolytes such as sodium and potassium, making it suitable for the dietary restrictions of renal care patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Renuris.